Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134264 · ClinicalTrials.gov registry record · Phase 3
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 15,067
- Enrollment target
NCT00134264 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 15,067 participants.
The verdict
NCT00134264, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15,067 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
Interventions
- DRUG atorvastatin
- DRUG torcetrapib/atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,067 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134264
The ClinicalTrials.gov registry entry for NCT00134264 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 15,067 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which atorvastatin is the first listed.
NCT00134264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134264 about?
NCT00134264 is a clinical study titled "A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
What is the current status of trial NCT00134264?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15,067 participants. The study started on 2004-07. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00134264?
The interventions under investigation include: atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00134264?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.